|Bid||51.33 x 28400|
|Ask||51.34 x 2100|
|Day's Range||51.03 - 52.80|
|52 Week Range||39.91 - 73.63|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021|
|Forward Dividend & Yield||2.80 (5.35%)|
|Ex-Dividend Date||Apr 29, 2020|
|1y Target Est||119.69|
Pharma and pesticides group Bayer's earnings guidance for this year fell short of investors' expectations on Thursday, raising questions about the strength of the agriculture business it boosted with the $63 billion takeover of Monsanto. Based on exchange rates at the end of 2020, Bayer said it expected 2021 adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of 10.5-10.8 billion euros ($12.8-$13.2 billion), down from 11.45 billion last year. Its shares were down 3.5% at 53.17 euros by 1300 GMT, erasing gains over the three previous trading sessions, as analysts said the lower-than-expected guidance pointed to a weaker seeds and pesticides unit.
Investors used to brush off AminJadavji's pitch to buy Elevate Farms’ vertical growingtechnology and produce stacks of leafy greens indoors withartificial light. Now, indoor farms are positioning themselves as one of thesolutions to pandemic-induced disruptions to the harvesting,shipping, and sale of food. "It's helped us change the narrative," said Jadavji, whosecompany runs a vertical farm in Ontario, and is building othersin New York and New Zealand.
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.